Bots, editor, reviewer, Administrators
13,951
edits
Feed:Recent Updates: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
==June 2025== | ==June 2025== | ||
; [[STEP-HFpEF]]: New summary # | ; [[STEP-HFpEF]]: New summary #520: Semaglutide in HFpEF+obesity but no DM | ||
; [[PACIFIC]]: New summary # | ; [[PACIFIC]]: New summary #519: Durvalumab vs. placebo as consolidation in NSCLC | ||
; [[ARIC A1c and CKD]]: New summary # | ; [[ARIC A1c and CKD]]: New summary #518: HbA1c and CKD risk in DM | ||
; [[Finnish Diabetes Prevention Study]]: New summary # | ; [[Finnish Diabetes Prevention Study]]: New summary #517: Lifestyle interventions to prevent diabetes | ||
==May 2025== | ==May 2025== | ||
; [[ACAS]]: New summary # | ; [[ACAS]]: New summary #516: CEA vs. medical therapy in asymptomatic carotid stenosis | ||
; [[RACE 7 ACWAS]]: New summary # | ; [[RACE 7 ACWAS]]: New summary #515: Delayed vs. early cardioversion in AF | ||
; [[RAPIDO]]: New summary # | ; [[RAPIDO]]: New summary #514: Chemo-RT vs. chemo in rectal cancer | ||
; [[HEAAL]]: New summary # | ; [[HEAAL]]: New summary #513: High- vs. low-dose losartan in heart failure | ||
==April 2025== | ==April 2025== | ||
; [[OPTION]]: New summary # | ; [[OPTION]]: New summary #512: LAA closure vs. anticoagulation in AF | ||
; [[LAAOS III]]: New summary # | ; [[LAAOS III]]: New summary #511: Surgical LAA occlusion in AF | ||
==March 2025== | ==March 2025== | ||
| Line 29: | Line 29: | ||
==February 2025== | ==February 2025== | ||
; [[AMBITION]]: New summary # | ; [[AMBITION]]: New summary #510: Combination of ambrisentan & tadalafil vs monotherapy in PAH | ||
==January 2025== | ==January 2025== | ||
; [[ARTESIA]]: New summary # | ; [[ARTESIA]]: New summary #509: Apixaban vs. aspirin in subclinical AF | ||
; [[PALACE]]: New summary # | ; [[PALACE]]: New summary #508: Penicillin allergy rule-out | ||
==December 2024== | ==December 2024== | ||
; [[DanGer Shock]]: New summary # | ; [[DanGer Shock]]: New summary #507: Impella in STEMI w/cardiogenic shock | ||
==November 2024== | ==November 2024== | ||
; [[BPROAD]]: New summary # | ; [[BPROAD]]: New summary #506: Intensive BP control in DM | ||
==October 2024== | ==October 2024== | ||
; [[AIDA-WP2]]: New summary # | ; [[AIDA-WP2]]: New summary #505: Nitrofurantoin vs. fosfomycin in UTI | ||
; [[FIDELIO-DKD]]: New summary # | ; [[FIDELIO-DKD]]: New summary #504: Mineralocorticoid antagonist in CKD/T2DM | ||
==September 2024== | ==September 2024== | ||
; [[EPIC-CAD]]: New summary # | ; [[EPIC-CAD]]: New summary #503: Edoxaban±antiplatelet in AF+stable CAD | ||
==August 2024== | ==August 2024== | ||
; [[PROMISE]]: New summary #502: Coronary CT for chest pain | |||
; [[CALORIES]]: New summary #501: Early parenteral vs. enteral feeds in ICU | ; [[CALORIES]]: New summary #501: Early parenteral vs. enteral feeds in ICU | ||
| Line 477: | Line 479: | ||
; [[SALT-ED]]: New summary #341: Balanced crystalloids vs. NS in non-critical ED patients | ; [[SALT-ED]]: New summary #341: Balanced crystalloids vs. NS in non-critical ED patients | ||
; [[Blood Pressure Reduction in Black Barbershops]]: New summary #340: PharmD-guided BP reduction for | ; [[Blood Pressure Reduction in Black Barbershops]]: New summary #340: PharmD-guided BP reduction for Black men | ||
==March 2018== | ==March 2018== | ||